Gyre Therapeutics (GYRE) has issued an announcement.
Gyre Therapeutics, Inc. has strengthened its leadership by appointing the highly experienced Dr. David Epstein as a Class II director and member of the Audit and Compensation Committees. With a robust background in biopharmaceuticals, including founding roles and executive positions at companies like PairX Bio and Black Diamond Therapeutics, Dr. Epstein’s expertise is poised to contribute significantly to Gyre’s strategic direction. His academic contributions and a strong track record in oncology research further solidify his role as a valuable addition to the company’s board.
Learn more about GYRE stock on TipRanks’ Stock Analysis page.
